Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.
Will Apollo, Max, Metropolis outshine peers in Q2? Here’s what analysts say
